Navigation Links
Hopkins-led team solves failed vaccine mystery
Date:12/15/2008

Research led by Johns Hopkins Children's Center scientists has figured out why a respiratory syncytial virus vaccine used in 1966 to inoculate children against the infection instead caused severe respiratory disease and effectively stopped efforts to make a better one. The findings, published online on Dec. 14 in Nature Medicine, could restart work on effective killed-virus vaccines not only for RSV but other respiratory viruses, researchers say. The new findings also debunk a popular theory that the 1966 vaccine was ineffective because the formalin used to inactivate the virus disrupted critical antigens, the substances that stimulate the production of protective antibodies.

Instead, researchers said, the problem occurred when the antibodies created by the vaccine failed to successfully bind to the real virus after exposure to it, thereby incapacitating it. Like vaccines against influenza and polio, the 1966 formalin-inactivated RSV vaccine produced antibodies, but these turned out to be defective ones with poor virus-binding ability.

"We have found the root cause of the problem, and in doing so we have uncovered clues that will help us design even safer and more effective vaccines in the future," says senior investigator Fernando Polack, M.D., an infectious disease specialist at Hopkins Children's.

More specifically, in a series of experiments, the research team discovered that the old RSV vaccine failed to trigger a "signaling" mechanism called toll-like receptor activation that helps the immune system recognize a virus and mount a defense against it. Toll-like receptor activation is the first in cascade of immune system responses that occur after infection, firing off signals to other immune cells telling them to produce and release antibodies.

First, the team compared immune system response in three groups of mice: those vaccinated with a placebo, those with a weakened form of the RSV virus, and those with inactivated or killed-virus vaccines. Researchers found that in the last group, the toll-like receptor activation was weak and led to the production of defective antibodies.

Next, they infused the vaccine with a substance that stimulates toll-like receptor activation to see if it would created antibodies better equipped to bind to and neutralize the virus. Indeed, mice vaccinated with the toll-like receptor stimulating form of the inactivated vaccine produced antibodies with better binding and virus-neutralizing ability. Mice immunized with this form of the vaccine had milder symptoms and less inflammation in the bronchi and the lungs when infected with the real RSV.


'/>"/>

Contact: Ekaterina Pesheva
epeshev1@jhmi.edu
410-516-4996
Johns Hopkins Medical Institutions
Source:Eurekalert

Related medicine news :

1. Lights Out For Bed Bugs as "BEST YET" Cedar Oil Solution Solves International Bed Bug Dilemma
2. Sealing off portion of intestinal lining treats obesity, resolves diabetes in animal model
3. APA resolves to play leading role in improving treatment for gender-variant people
4. Senetek PLC Resolves Dispute With Marketer of Pyratine-6(TM) on Most Favorable Terms
5. Empis Hybresis Solves Pain Points for Physical Therapists
6. MedImmune Resolves FDA Observations Regarding Manufacturing Process for FluMist(R)
7. McKesson Corporation Agrees to Pay More Than $13 Million to Settle Claims That It Failed to Report Suspicious Sales of Prescription Medications
8. Drug Failed to Reduce Heart Attack Risk After Bypass
9. UFE Highly Effective in Cases Where Focused Ultrasound to Treat Uterine Fibroids Failed
10. PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
11. Fallout From Failed AIDS Vaccine Could Dampen Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... September 19, 2017 , ... CTNext , Connecticut’s ... Awards (EIA), held this past Thursday night at The Space in Hamden. ... their innovative project ideas to a panel of judges for an opportunity to ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... rallying cry to Americans to watch for the discomforts and hidden dangers of ... to senior citizens, everyone is at risk for developing fungal infections on the ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... unveiled the MirixaPro 6.0 platform. As the industry’s leading Medication Therapy Management ... delivered. Based on industry research and market feedback, the latest version of ...
(Date:9/19/2017)... Philadelphia, PA (PRWEB) , ... September 19, 2017 ... ... high-quality orthopedic dog beds, has been officially recognized for its September 2016 donation ... , The company recently received three awards and honors for its contribution ...
(Date:9/19/2017)... ... ... Public outrage over the toxins that exist in tap water and the lack ... itself to research, develop and ultimately supply consumers with healthy drinking water alternatives. Vitev ... alkaline water technologies, water filtration systems, and consumer education. , ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... , Sept. 8, 2017 Dealmed Medical Supplies, ... supplier of medical equipment, supplies, drugs, vaccines, and specialty ... entered into an agreement to acquire Vantage Medical Supplies, ... in Holtsville, New York . ... supplying new and emerging medical practices, will operate under ...
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), the company commercializing ... Pharma AG to distribute NuvoAir,s spirometry technology to physicians worldwide. ... platform and Novartis, commitment to address the unmet medical needs ... ... "We are ...
(Date:9/6/2017)... , Sept. 6, 2017   PDI , a ... it will host an educational session focused on the ... infection (CLABSI) prevention at the 2017 Annual Scientific Meeting ... will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
Breaking Medicine Technology: